Although multiple biomarkers have been associated with the prediction of immunotherapy effect, including the expression of programmed cell death protein 1 (PD-1), PD-L1 and tumor mutation burden (TMB), it is still less than satisfactory to select BLCA patients who are likely to benefit most from immunotherapy (4). This evidence concerns the gene PDCD1 and neoplasm.